Buradasınız

BIOBOTS ADVANCE IN ATHEROSCLEROSIS AND IN CANCER: REVIEW

Journal Name:

Publication Year:

Abstract (2. Language): 
Biobots a kind of nanorobots, another application of nanotechnology, is the creation of muscle-powered nanoparticles having the ability to transfer information into cells, gives the potential of replacing lost biological function of many tissues such as sinoatrial node. This effect can lead to treatment of diseases which otherwise would be fatal or difficult to cure for human. Nanotechnology mainly consists of the processing, consisting of processing of separation, consolidation and deformation of materials by one atom or by one molecules. Many novel nanoparticles and nanodevices are expected to be used, with an enormous positive impact on human health. The vision is to improve health by enhancing the efficacy and safety of nanosystems and nanodevices. Products based on nanotechnology in medicine and medical technology are reaching the market, with an anticipated enormous positive impact on human health, in the coming years. Nanotechnology also plays a key role in the interventional therapeutic approach of atherosclerosis and Coronary Artery disease (CAD), by improving the biocompatibility of intracoronary stents and by regulating the main limit factors for Percutaneous Trans luminal Coronary Angioplasty(PTCA) at a molecular level via nanoparticles.
301
314

REFERENCES

References: 

1. Jong WH de, Roszek B., Geertsma R.E.,
“Nanotechnology in medical applications:
possible risks for human health”,
RIVMreport 265001002, 2005. RIVM,
National Institute for Public Health and the
Environment, Bilthoven, The Netherlands,
2005.
2. Roszek B, Jong WH de, Geertsma RE.
“Nanotechnology for medical
applications:state-of-the-art in materials
and devices”, RIVM report 265001001,
2005. RIVM, National Institute for Public
Health and the Environment, Bilthoven, The
Netherlands, 2005.
3. http://www.nec.com/global/corp/H0602
.html,http://,www.gatech.edu/newsroom/
release, www.nanotech-now.com/
news.cgi?story_id=10065.
4. www.ijpbs.net
5. Morton AC, Crossman D, Gunn J. The
influence of physical stent parameters upon
restenosis. PathologieBiologie 2004;52:196-
205.
6. http://www.pharmsci.neu.edu/researchc
enters/center_cardiotargeting.html
7. Logothetidis S, Gioti M, Lousinian S,
Fotiadou S, “Haemo compatibility studies
on carbon-based thin films by
ellipsometry”. Thin Solid Films2004;
482:126
8. Chen ×, Fujise Ê. “Restenosis: Emerging
molecular targets. Going beyond drugeluting
stents”. Drug Discovery Today:
Disease Mechanisms/Cardiovascular
diseases 2005; 2:ÍïI
9. Elwing H, “Protein absorption and
ellipsometry in biomaterial research”,
Biomaterials 1998; 19:397; Garcia-Caurel Å,
Nguyen J, Schwartz L, Drévillon B,
“Application of FTIR ellipsometry to detect
and classify microorganisms”, Thin Solid
Films 2004; 455:722;”Moving ellipsometry
from materials to medicine”. III-Vs
Review2004; 17:4
10. Zharov V, Galitovsky V, Viegas M.
“Photothermal detection of local thermal
effects during selective
nanophotothermolysis”. ApplPhysLett2003;
83:4897
11. Zharov VP, Galitovsly V, Viegas M.
“Photothermal guidance of selective
photothermolysis with nanoparticles”. Proc
SPIE 2004; 5319:291
12. Nanomedicine; An ESF – European
Medical Research Councils (EMRC) Forward
Look report 2005, (www.nanoforum.org)
Review Article CODEN: IJPRNK ISSN: 2277-8713
Mitisha Bhatt, IJPRBS, 2013; Volume 2(5):301-314 IJPRBS
Available Online at www.ijprbs.com
314
13. Mitsakakis Ê, Lousinian S, Logothetidis S.
“Early stages of human plasma proteins
adsorption probed by Atomic Force
Microscope”, Biomolecular Engineering (to
be published in 2006)
14. www.molec.com/ what_is_afm.html
15. Wei C. “Highlights of the first annual
meeting of the American Academy of
Nanomedicine”. Nanomedicine:
Nanotechnology, Biology and Medicine
2005; 1:351

Thank you for copying data from http://www.arastirmax.com